Tumor markers and colorectal cancer: utility in management.
Colorectal cancer (CRC) is a leading cause of morbidity and mortality. Although genetic testing can screen for rare hereditary CRC syndromes, there is no ideal means of screening for sporadic forms of CRC. This review will focus on markers that are currently used in the management of sporadic CRC and their limitations, as well as possible future clinical applications.
Crawford
Nigel P S
NP
Price Institute of Surgical Research, Department of Surgery, University of Louisville, Kentucky 40292, USA.
Colliver
Daniel W
DW
Galandiuk
Susan
S
D011125:Adenomatous Polyposis Coli / Q000175:diagnosis / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000628:therapy; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000175:diagnosis; D005819:Genetic Markers; D006801:Humans; D009780:Occult Blood; D009955:Ornithine Decarboxylase / Q000097:blood; D011379:Prognosis; D016719:Radioimmunodetection
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen; D005819:Genetic Markers; D009955:Ornithine Decarboxylase